KPTI
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (KPTI) has 14 SEC Form 4 filings (20 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 30, 2026.
- Industry:Biotechnology
- CEO:Richard A. Paulson
- Employees:228
- HQ:Newton, MA, US
- IPO:2013-11-06
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$40K
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$160.7M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| EVP, Chief Development Officer | Sale | 189 | $1K | Jul 30 | SEC ↗ | |
| EVP & Chief Medical Officer | Sale | 408 | $4K | May 15 | SEC ↗ | |
Mano MichaelFirst filing | EVP, CLO&Secretary | Sale | 266 | $3K | May 15 | SEC ↗ |
Poulton StuartFirst filing | EVP, Chief Development Officer | Sale | 403 | $4K | May 15 | SEC ↗ |
Abate KristinFirst filing | Chief Accounting Officer | Sale | 53 | $504 | May 15 | SEC ↗ |
Paulson Richard A.First filing | President and CEO | Sale | 2,203 | $21K | May 15 | SEC ↗ |
Cheng Sohanya RoshanFirst filing | EVP & Chief Commercial Officer | Sale | 324 | $3K | May 15 | SEC ↗ |
Rangwala ReshmaFirst filing | EVP & Chief Medical Officer | Sale | 449 | $4K | Apr 22 | SEC ↗ |
Related companies
Karyopharm Therapeutics Inc. is in the Healthcare sector.